Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Organon & Co. due to misleading statements regarding its capital allocation strategy, particularly concerning dividends and debt reduction following the acquisition of Dermavant [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Organon, with a deadline of July 22, 2025, for investors to seek the role of lead plaintiff [3]. - Investors who suffered losses exceeding $75,000 in Organon between October 31, 2024, and April 30, 2025, are encouraged to contact the firm to discuss their legal rights [1][3]. Group 2: Financial Impact and Stock Performance - Organon provided positive statements about its capital allocation strategy, emphasizing regular dividends as a top priority, while concealing adverse facts about its financial priorities [5]. - Following the revelation of these misleading statements, Organon's stock price dropped from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in one day [6].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for misleading investors regarding its dividend policy following the acquisition of Dermavant [1][3]. Company Overview - Organon & Co. is a healthcare company focused on women's health, headquartered in Jersey City, NJ [2]. - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2]. Financial Developments - Following the Dermavant acquisition, Organon increased its debt but assured investors it would maintain its dividend as its "1 capital allocation priority" [3]. - On May 1, 2025, Organon announced a significant reduction in its dividend payout from $0.28 per share to $0.02 per share, indicating a shift in capital allocation priorities towards deleveraging [3]. - This announcement led to a decline in Organon's stock price by $3.48 per share, approximately 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [3].

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/organon-co-lawsuit-submission-for ...

Core Insights - Investors are comparing Organon (OGN) and Medpace (MEDP) to determine which stock offers better value for investment [1] Valuation Metrics - Organon has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision trend compared to Medpace, which has a Zacks Rank of 3 (Hold) [3] - OGN's forward P/E ratio is significantly lower at 2.65, while MEDP's forward P/E is 25.65, suggesting OGN may be undervalued [5] - The PEG ratio for OGN is 1.01, indicating a better valuation relative to its expected earnings growth compared to MEDP's PEG ratio of 5.88 [5] - OGN's P/B ratio stands at 4.87, while MEDP's P/B ratio is much higher at 15.79, further supporting OGN's valuation advantage [6] - OGN has a Value grade of A, while MEDP has a Value grade of C, indicating a stronger overall value proposition for OGN [6]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to allegations of misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1]. Group 1: Allegations and Impact - The complaint alleges that Organon's management provided overly positive statements while concealing critical information about the company's priorities, particularly regarding its debt reduction strategy after acquiring Dermavant [1]. - Following the revelation of these issues, Organon's regular quarterly dividend was reduced by 70%, leading to a significant drop in stock price from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, representing a decline of over 27% in just one day [1]. Group 2: Class Action Details - Shareholders who purchased shares of Organon during the class period from October 31, 2024, to April 30, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for July 22, 2025 [2]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress, with no cost or obligation to participate [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices, aiming to ensure companies adhere to responsible business practices [3].

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/organon-co-loss-submission-form/?id=155074&from=3 CLASS PERIOD: October 31, 2024 to Apri ...

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and investors have until July 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased the company's debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, claiming it was the "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

NEW YORK, July 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid= ...

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly misleading investors regarding its capital allocation strategy, particularly concerning its debt reduction efforts and dividend payouts [1][2][3]. Allegations - The lawsuit claims that during the class period, Organon misrepresented its commitment to regular dividends as its "1 capital allocation priority," while concealing the importance of its debt reduction strategy following the acquisition of Dermavant [2][3]. - The complaint highlights that the company reduced its regular quarterly dividend by 70%, from $0.28 to $0.02, which was not disclosed to investors during the class period [3]. Impact of Disclosure - The truth about the company's financial strategy was revealed on May 1, 2025, when Organon announced its first quarter results, leading to a significant drop in its stock price from $12.93 to $9.45, a decline of over 27% [4].